16.0k views
0 votes
Virtually all patients with polycythemia vera have a mutation in _______, a non-receptor (cytoplasmic) tyrosine kinase associated with the EPO receptor (constitutive activation).

1 Answer

5 votes

Final answer:

Patients with polycythemia vera have a mutation in erythropoietin (EPO), a hormone that stimulates red blood cell production in the bone marrow. Synthetic EPO is used both as a banned substance by athletes to enhance performance, and medically to treat anemia.

Step-by-step explanation:

Virtually all patients with polycythemia vera have a mutation in erythropoietin (EPO), a non-receptor (cytoplasmic) tyrosine kinase associated with the EPO receptor (constitutive activation). EPO is a glycoprotein hormone secreted by the kidneys in response to low oxygen levels. It stimulates the production of red blood cells in the bone marrow. Some athletes use synthetic EPO as a performance-enhancing drug to increase their red blood cell counts and improve oxygen delivery, but it is also used medically to treat certain types of anemia.

User Alberto Adami
by
8.4k points